# Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment

> **NCT07467330** · PHASE3 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 258 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** dalpiciclib + capecitabine + endocrine therapy
- **DRUG:** dalpiciclib + endocrine therapy

## Key facts

- **NCT ID:** NCT07467330
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-15
- **Primary completion:** 2031-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07467330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07467330, "Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07467330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*